Literature DB >> 8093222

The adenovirus E1A 12S product displays functional redundancy in activating the human proliferating cell nuclear antigen promoter.

C Kannabiran1, G F Morris, C Labrie, M B Mathews.   

Abstract

The adenovirus E1A 243R oncoprotein stimulates expression from the promoter of the human proliferating cell nuclear antigen (PCNA). To gain insight into the mechanism of activation, we analyzed deletion and point mutations of the 243R protein for their abilities to activate PCNA promoter-directed reporter gene expression upon cotransfection into HeLa cells. Large deletions that in combination span the entire protein severely impaired the ability of E1A 243R to induce PCNA expression. Smaller deletions and specific point mutations that target specific E1A-binding proteins were less deleterious to PCNA induction. The data suggest that E1A activates transcription of the PCNA gene by multiple mechanisms and that, of the known 243R-associated proteins, p300 and p107-cyclin A can mediate the response while p105-RB does not appear to participate. Presumably, the functional redundancy ensures that 243R can activate expression of this essential DNA replication protein regardless of cell type and physiological conditions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093222      PMCID: PMC237388     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

Review 1.  Transforming collaborations between ras and nuclear oncogenes.

Authors:  H E Ruley
Journal:  Cancer Cells       Date:  1990 Aug-Sep

2.  Adenovirus E1a prevents the retinoblastoma gene product from complexing with a cellular transcription factor.

Authors:  L R Bandara; N B La Thangue
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

3.  The E2F transcription factor is a cellular target for the RB protein.

Authors:  S P Chellappan; S Hiebert; M Mudryj; J M Horowitz; J R Nevins
Journal:  Cell       Date:  1991-06-14       Impact factor: 41.582

4.  Cell cycle regulation of the E2F transcription factor involves an interaction with cyclin A.

Authors:  M Mudryj; S H Devoto; S W Hiebert; T Hunter; J Pines; J R Nevins
Journal:  Cell       Date:  1991-06-28       Impact factor: 41.582

5.  Adenovirus E1A proteins can dissociate heteromeric complexes involving the E2F transcription factor: a novel mechanism for E1A trans-activation.

Authors:  S Bagchi; P Raychaudhuri; J R Nevins
Journal:  Cell       Date:  1990-08-24       Impact factor: 41.582

6.  A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product.

Authors:  S Huang; W H Lee; E Y Lee
Journal:  Nature       Date:  1991-03-14       Impact factor: 49.962

7.  Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B.

Authors:  J Pines; T Hunter
Journal:  Nature       Date:  1990-08-23       Impact factor: 49.962

8.  The retinoblastoma protein copurifies with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F.

Authors:  S Bagchi; R Weinmann; P Raychaudhuri
Journal:  Cell       Date:  1991-06-14       Impact factor: 41.582

9.  Human cyclin A and the retinoblastoma protein interact with similar but distinguishable sequences in the adenovirus E1A gene product.

Authors:  A Giordano; C McCall; P Whyte; B R Franza
Journal:  Oncogene       Date:  1991-03       Impact factor: 9.867

10.  Analysis of the proliferating cell nuclear antigen promoter and its response to adenovirus early region 1.

Authors:  G F Morris; M B Mathews
Journal:  J Biol Chem       Date:  1990-09-25       Impact factor: 5.157

View more
  16 in total

1.  Selective induction of p53 and chemosensitivity in RB-deficient cells by E1A mutants unable to bind the RB-related proteins.

Authors:  A V Samuelson; S W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

2.  Transcriptional repression and growth suppression by the p107 pocket protein.

Authors:  P Starostik; K N Chow; D C Dean
Journal:  Mol Cell Biol       Date:  1996-07       Impact factor: 4.272

3.  Role of p300-family proteins in E1A oncogene induction of cytolytic susceptibility and tumor cell rejection.

Authors:  J L Cook; C K Krantz; B A Routes
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

4.  Neuralization of the Xenopus embryo by inhibition of p300/ CREB-binding protein function.

Authors:  Y Kato; Y Shi; X He
Journal:  J Neurosci       Date:  1999-11-01       Impact factor: 6.167

5.  HMG-I(Y) and the CBP/p300 coactivator are essential for human papillomavirus type 18 enhanceosome transcriptional activity.

Authors:  Isabelle Bouallaga; Sébastien Teissier; Moshe Yaniv; Françoise Thierry
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

6.  Transcription factors RFX1/EF-C and ATF-1 associate with the adenovirus E1A-responsive element of the human proliferating cell nuclear antigen promoter.

Authors:  C Labrie; B H Lee; M B Mathews
Journal:  Nucleic Acids Res       Date:  1995-09-25       Impact factor: 16.971

7.  Complementary functions of E1a conserved region 1 cooperate with conserved region 3 to activate adenovirus serotype 5 early promoters.

Authors:  H K Wong; E B Ziff
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

8.  A complex promoter element mediates transactivation of the human proliferating cell nuclear antigen promoter by the 243-residue adenovirus E1A oncoprotein.

Authors:  C Labrie; G F Morris; M B Mathews
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

9.  Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis.

Authors:  J Shisler; P Duerksen-Hughes; T M Hermiston; W S Wold; L R Gooding
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

10.  Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53.

Authors:  G F Morris; J R Bischoff; M B Mathews
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.